WO2019028248A1 - Systèmes et méthodes pour améliorer l'administration d'agents actifs topiques - Google Patents

Systèmes et méthodes pour améliorer l'administration d'agents actifs topiques Download PDF

Info

Publication number
WO2019028248A1
WO2019028248A1 PCT/US2018/045000 US2018045000W WO2019028248A1 WO 2019028248 A1 WO2019028248 A1 WO 2019028248A1 US 2018045000 W US2018045000 W US 2018045000W WO 2019028248 A1 WO2019028248 A1 WO 2019028248A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
area
topical
acid
polymer
Prior art date
Application number
PCT/US2018/045000
Other languages
English (en)
Inventor
Amy Newman BROWN
John E. Kuleza
Original Assignee
Young Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Young Pharmaceuticals, Inc. filed Critical Young Pharmaceuticals, Inc.
Publication of WO2019028248A1 publication Critical patent/WO2019028248A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/88—Polyamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the disclosure generally relates to systems and methods for improving deliver ⁇ ' of topical actives and, more specifically, systems and methods for improving delivery of topical actives by using polymers to tension the skin.
  • a system for improving the delivery of one or more topical actives includes at least one polymer effective to mechanically tension an area of skin to which the system is applied and the one or more topical actives,
  • a method for improving the delivery of one or more topical actives includes applying to an area of skin a composition including at least one polymer effective to mechanically tension an area of skin and the one or more topical actives.
  • the one or more topical actives are delivered to the area of skin at an improved rate or to improved depths as compared to a rate or depth of delivery achieved by application of the one or more topical actives applied to the area of skin alone.
  • Various aspects provide a system for improving delivery of one or more topical actives to the skin of a subject
  • the system includes at least one polymer effective to mechanically tension an area of skin to which the system is applied and optionally one or more topical actives.
  • the polymer effective to mechanically tension the area of skin may be an acrylate copolymer.
  • the topical actives are delivered to the area of skin at an improved rate or to an improved depths as compared to a rate or depths of delivery achieved by application of the one or more topical actives applied to the area of skin alone.
  • the system includes at least one polymer that is effective to mechanically tension an area of skin to which the system is applied.
  • a polymer as provided undergoes a contraction after application to the skin such as due to water loss in the polymer or other activity.
  • the contraction causes a tension to the skin as the polymer is adhered to the skin surface. This tension is believed to increase the accessibility of the active to the intercellular space within the skin so that more effective delivery to skin depths is achieved.
  • polymer encompasses polymers produced from at least two identical or different monomers and could include polymers having more than two comonomers such as terpolymers, tetrapolymers, etc. Without being bound by theory, it is believed that the combination of the polymer to tension the area of skin along with one or more topical actives may increase delivery of the topical active by tensioning the skin ceils to enable the topical active(s) to contact and enter the intercellular spaces in the skin.
  • the polymer may be an acrylate copolymer. Although acrylate copolymers are specifically described herein as being suitable for use in various aspects, other polymers are contemplated, provided they are effective to mechanically tension the skin.
  • the polymer may have a backbone and a plurality of pendant groups thereon that are pendant ionic or ionizable groups, or pendant groups having at least one permanent dipole that may include an alcohol, thiol, ester, amide, imide, imine, or nitrile moiety.
  • the pendant groups attached to the main polymer chain can be present in the monomer(s) at the time of polymerization, or they can be formed by post-polymerization reaction, for example post-polymerization salification or hydrolysis of a salifiable or hydrolysabie functional group that was present as, or as part of, a substituent on the monomer(s) at the time of polymerization.
  • the polymer optionally comprises a tensing polymer, such as a random linear copolymer.
  • the tensing polymers may include copolymers of methyl methacrylate/methacrylic acid, copolymers of methyl methacrylate/acrylic acid; copolymers of ethyl methacrylate/methacrylic acid; copolymers of ethyl methacrylate/acrylic acid; copolymers of isobutyl methacrylate/methacrylic acid; copolymers of acrylates/dimemylaminoethyl methacrylate; copolymers of isobutyl methacrylate/acrylic acid; copolymers of benzyl methacrylate/methacrylic acid; copolymers of benzyl methacrylate/acrylic acid; copolymers of benzyl methacrylate/methacryiic acid; copolymers of benzyl acrylate/acrylic acid
  • Additional polymers may also include polymers described in U.S. Patent No. 9,724,363, Such polymers may include at least one alkenyl functionalized organopolysiloxane, wherein the at least one alkenyl functionalized organopolysiloxane comprises vinyl terminated polydimethylsiloxane; vinyl terminated diphenyl siioxane-dimethyisiioxane copolymers; vinyl terminated polyphenylmethylsiloxane, vinylphenylmethyl terminated vinylphenylsiloxane- phenylmethylsiloxane copolymer; vinyl terminated trifluoropropylmethylsiloxane- dimethylsiloxane copolymer; vinyl terminated diethyl siloxane-dimethylsiloxane copolymer; vinylmethyisiioxane-dimethylsiloxane copolymer, trimethylsiloxy terminated; vinylmethylsiloxane
  • the polymer may be an acryl ate copolymer, such as polyacrylate-21 and copolymers of acryl ates/dimethylaminoethyl methacrylate.
  • acryl ate copolymer such as polyacrylate-21 and copolymers of acryl ates/dimethylaminoethyl methacrylate.
  • Such polymers are commercially available as SYNTRAN® PC 5100, from Interpolymer Corporation.
  • the polymer may also comprise combinations or derivations of any of the aforementioned polymers or copolymers.
  • the polymer may be included in the system in any suitable amount from about 0.0001 wt% to about 99.99 wt% based on a total weight of the composition.
  • the polymer is present at a weight percent of 99.99, 99.9, 99.5, 99, 98.5, 98, 97.5, 97, 96.5, 96, 95.5, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, /, 6, 5, 4, 3, 2, 1, 0,5, 0.1, 0.01, 0.001, 0.0001, or any level in between or any range between 99.99% and 0.0001 % by weight.
  • the polymer is present in the amount of between about 10% to about 30% by weight, between about 15% to about 25% by weight, or at about 20% by weight based on the total weight of the composition,
  • the system optionally further includes one or more topical actives, but aspects without such a topical active are also provided.
  • the topical active may be, for example, a moisturizer, a retinoid, a peptide or modified peptide, or other composition that has a physiological effect on the skin of as subject or a cell within the skin of a subject.
  • the topical active includes a retinoid
  • the retinoid may be, by way of example and not limitation, retinal, retinoic acid, retinyl ester, retinol, tretinoin or esters or amides thereof, isotretinoin or esters or amides thereof, adapalene, tazarotene, alitretinoin, etretinate, acitretin, adapalene, bexarotene, or tazarotene, combinations thereof, or derivatives thereof.
  • Specific examples of retinoids include those described in U.S. Patent Nos.
  • the topical active includes a moisturizer
  • the moisturizer may be, by way of example and not limitation, propylene glycol, allantoin, acetamine MEA, oat protein, hyaluronic acid, combinations thereof, or derivatives thereof.
  • Other active ingredients such as UV blocking agents, antimicrobial agents, anti-wrinkle agents, anti-oxidants, vitamins, minerals, and the like may further be included as topical actives, depending on the particular aspect. Still other actives are contemplated, provided they are effective when applied to a bodily surface, such as an area of skin,
  • a topical active is a peptides or modified peptide.
  • a peptide or modified peptide optionally has from 1 to 50 amino acids or any value or range therebetween.
  • a peptide includes from 1 to 7 amino acids,
  • Amino acids present in a peptide optionally include the common amino acids alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, and tyrosine as well as less common naturally occurring amino acids, modified amino acids or synthetic compounds, such as aipha- asparagine, 2-aminobutanoic acid or 2-aminobutyric acid, 4-aminobutyric acid, 2-aminocapric acid (2-aminodecanoic acid),
  • the topical active is a modified peptide.
  • the peptide modified is by the addition of a fatty acid, optionally a fatty acid with an alkyl, alkenyl, or alkynyl linear or branched group of 5 to 25 carbons in length.
  • the fatty acid is a naturally occurring fatty acid.
  • the modified peptide may be palmitoyl tripeptide- 1 or palmitoyl tetrapeptide-7.
  • An illustrative commercial example of a modified peptide is MATRIXYL® 3000, from Sederma.
  • the topical active may be included in the system in any suitable amount from about ⁇ wt% to about 99 wt% based on a total weight of the composition, depending on the particular aspect.
  • the topical active is present at a weight percent of 30, 29, 28, 27, 26, 25, 24, 23, 22, 21 , 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, 0.1, 0.01, 0.001, 0.0001, or any level in between or any range between 30% and 0.0001% by weight.
  • the topical active is present in the amount of between about 10% to about 30% by weight, between about 15% to about 25% by weight, or at about 20% by weight based on the total weight of the composition.
  • a topical active is optionally present in a composition at a relative molar ratio to the polymer.
  • the relative molar ratio of polymer to topical active may be in the range of from about 99.99:0.01 to 0.01 :99.99.
  • the relative molar ratio of the topical active to a polymer may in the range of from about 99.9:0.1 to 0.1 :99.9, 99.5:0.5 to 0.5:99.5, 99: 1 to 1 :99, 98.5: 1.5 to 1.5:98.5, 98:2 to 2:98, 97.5:2.5 to 2.5:97.5, 97:3 to 3 :97, 96:4 to 4:96, 95:5 to 5:95, 90: 10 to 10:90, 80:20 to 20:80, 70:30 to 30:70, 60:40 to 40:60, 50:50, or any ratio in between 99.99:0,01 and 0,01 :99.99 by weight,
  • the polymer and the one or more topical actives may be combined into a composition for topical application to an area of skin on an individual.
  • the polymer and the one or more topical actives may be mixed together, with or without additional ingredients, to form a cream, foam, gel, lotion, or ointment. Additional ingredients may include, as non-limiting examples, preservatives, antimicrobial agents, antifungal agents, antibacterial agents, or the like.
  • the polymer and one or more topical actives may further be combined with a hydrogel.
  • the polymer and topical active may be included in a hydrogel.
  • a hydrogel is polymeric material that is substantially interfiled with water or other aqueous or nonaqueous fluid.
  • the hydrogel may include a network of hydrophiiic polymer chains dispersed in water.
  • the hydrogel may include over 50%, over 60%, over 70%, over 80%, or even over 90% water.
  • the hydrogel polymers are not particularly limited, although in various aspects, the hydrogel is a photo-curable hydrogel .
  • hydrogel polymer is a naturally occurring polymer or a synthetic polymer.
  • Illustrative examples of natural hydrogel polymers include, but are not limited to chitosan, dextran, hyaluronic acid, and alginate.
  • Illustrative examples of synthetic hydrogel s include but are not limited to hydrogels comprising monomers of vinyl acetate, acryl amide, ethylene glycol, and lactic acid.
  • Illustrative examples of synthetic hydrophiiic polymers include polyethylene oxide, polyphenylene ether, polyphenyiene oxide, and polyethylene glycol, or a combination thereof.
  • the hydrogel polymer is present at a weight percent of from 25, 24, 23, 22, 21 , 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 , 0,5, 0, 1 , 0,01, 0.001, 0.0001 , or any level in between or any range between 25% and 0.0001 % by weight.
  • the hydrogel polymer is present in the amount of between about 0.1% to about 10% by weight, between about 1% to 9% by weight, between about 2% to about 7% by weight, between about 3%> to 6% by weight, or at about 5%> by weight based on the total weight of the composition.
  • the system may be in the form of a patch formed of the composition including the polymer and optionally the one or more topical actives.
  • the topical active may, for example, be applied to a surface of the patch, or may be otherwise infused into a thickness of the patch.
  • the composition may be incorporated into the system during formation of the patch by mixing the system and the one or more topical actives with the components for manufacturing the patch. Other methods of applying the composition to the patch are contemplated.
  • the polymer, hydrophilic polymer, active, peptide or modified peptide or any combination thereof may be applied to a substrate for storage and final application to a desired site of action.
  • a substrate may be any film or other surface with suitable properties to allow for proper storage, shape retention, application or other desired property or combination thereof.
  • an area of skin to be treated with the composition may be contacted with the surface of the patch.
  • the composition may be applied to the area of skin using an applicator.
  • the applicator may be, for example, a sponge, brush, finger, or the like.
  • the area of skin to which the composition is applied is not particularly limited and may be, for example, an area on a face (e.g., eye, area immediately under or beside the eye, cheek, forehead, etc.), an arm, or a chest, a leg, or any component of an arm or leg such as a knee or triceps area, or a stomach or back region, although other body parts are also contemplated.
  • the one or more topical actives are delivered to the area of skin.
  • the topical active is delivered to the area of skin at an improved (i.e., faster) rate or to a greater depth, or in greater amounts as compared to a rate, depth, or amount of delivery achieved when the one or more topical actives are applied to the area of skin alone or as part of a composition that does not include the polymer.
  • a Franz diffusion ceil model may be used to determine the rate of deliveiy of the topical active.
  • a topical active delivery composition is formulated to include the following ingredients in proportions listed in Table 1 as Formula A.
  • the polymer and peptide or modified peptide, or active may be combined in an inert, optionally stainless steel, container and intermixed such as by propeller mixing at room temperature until a uniform mixture is created. Once uniformity is achieved, the mixture may then be combined with or polymerized into a hydrophilic polymer in water (e.g. hydrogel) to achieve a final formation.
  • Illustrative exemplary formulations may be:
  • a topical active delivery composition is fonnulated to include the following ingredients in proportions listed in Table 2 as Formula B.
  • a topical active delivery composition is formulated to include the following ingredients in proportions listed in Table 3 as Formula C.
  • a topical active delivery composition is formulated to include the following ingredients in proportions listed in Table 4 as Formula D,
  • a topical active delivery composition is formulated to include the following ingredients in proportions listed in Table 6 as Formula F.
  • a topical active delivery composition is formulated to include the following ingredients in proportions listed in Table 7 as Formula G, Table 7: Formula G
  • a topical active deliver ⁇ ' composition is fonnulated to include the following ingredients in proportions listed in Table 8 as Formula H.
  • a topical active delivery composition is formulated to include the following ingredients in proportions listed in Table 8 as Formula H.
  • a topical active deliver ⁇ ' composition is fonnulated to include the following ingredients in proportions listed in Table 9 as Formula I.
  • a topical active delivery composition is formulated to include the following ingredients in proportions listed in Table 10 as Formula J.
  • a topical active delivery composition is formulated to include the following ingredients in proportions listed in Table 11 as Formula K.
  • Table 11 Formula K
  • a topical active delivery composition is formulated to include the followi ingredients in proportions listed in Table 12 as Formula L.
  • Table 12 Formula L
  • a topical active delivery composition is formulated to include the following ingredients in proportions listed in Table 13 as Formula M.
  • Table 13 Formula M
  • a topical active deliver ⁇ ' composition is formulated to include the following ingredients in proportions listed in Table 14 as Formula .
  • Patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains.
  • Each patent, application or publication is incorporated herein by reference to the same extent as if each individual patent, application or publication was specifically and individually stated as incorporated herein by reference for the specific teaching for with each reference is cited and additionally for entirety of their contents including text, figures, and references. Citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.
  • the foregoing description is illustrative of particular aspects of the disclosure, but is not meant to be a limitation upon the practice thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un système permettant d'améliorer l'administration d'un ou de plusieurs agents actifs topiques, qui comprend au moins un polymère efficace pour tendre mécaniquement une zone de la peau à laquelle le système est appliqué, et le ou les agents actifs topiques. Une méthode qui permet d'améliorer l'administration d'un ou de plusieurs agents actifs topiques comprend l'application sur une zone de la peau d'une composition comprenant au moins un polymère efficace pour tendre mécaniquement une zone de la peau, et le ou les agents actifs topiques. Le ou les agents actifs topiques sont administrés au niveau de la zone de la peau à un taux amélioré par rapport au taux d'administration obtenu par l'application du ou des actifs topiques appliqués seuls au niveau de la zone de la peau.
PCT/US2018/045000 2017-08-02 2018-08-02 Systèmes et méthodes pour améliorer l'administration d'agents actifs topiques WO2019028248A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762540145P 2017-08-02 2017-08-02
US62/540,145 2017-08-02

Publications (1)

Publication Number Publication Date
WO2019028248A1 true WO2019028248A1 (fr) 2019-02-07

Family

ID=65234118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/045000 WO2019028248A1 (fr) 2017-08-02 2018-08-02 Systèmes et méthodes pour améliorer l'administration d'agents actifs topiques

Country Status (1)

Country Link
WO (1) WO2019028248A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030161870A1 (en) * 1999-12-16 2003-08-28 Tsung-Min Hsu Dual enhancer composition for topical and transdermal drug delivery
US20090076257A1 (en) * 2002-03-12 2009-03-19 Fidia Farmaceutici S.P.A. Ester Derivatives of Hyaluronic Acid for the Preparation of Hydrogel Materials by Photocuring
US20120087888A1 (en) * 2010-04-12 2012-04-12 Pernodet Nadine A Bio-Mechanical Stimulation Of Collagen Synthesis In Skin Cells And Reduction Of Appearance Of Fine Lines And Wrinkles On The Skin
US20130078299A1 (en) * 2011-04-11 2013-03-28 Alliqua, Inc. Transdermal Patches Having Ionized Beam Crosslinked Polymers and Improved Release Characteristics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030161870A1 (en) * 1999-12-16 2003-08-28 Tsung-Min Hsu Dual enhancer composition for topical and transdermal drug delivery
US20090076257A1 (en) * 2002-03-12 2009-03-19 Fidia Farmaceutici S.P.A. Ester Derivatives of Hyaluronic Acid for the Preparation of Hydrogel Materials by Photocuring
US20120087888A1 (en) * 2010-04-12 2012-04-12 Pernodet Nadine A Bio-Mechanical Stimulation Of Collagen Synthesis In Skin Cells And Reduction Of Appearance Of Fine Lines And Wrinkles On The Skin
US20130078299A1 (en) * 2011-04-11 2013-03-28 Alliqua, Inc. Transdermal Patches Having Ionized Beam Crosslinked Polymers and Improved Release Characteristics

Similar Documents

Publication Publication Date Title
US10493178B2 (en) Hydrogel compositions
US6211296B1 (en) Hydrogels containing substances
ATE285225T1 (de) Filmbildendes hautreinigungsmittel
JP7402925B2 (ja) 抗菌ペプチド刺激性清浄組成物
JP6071050B2 (ja) 皮膚用化粧料
CN106068118B (zh) 卸妆化妆料和片制品
WO2017044546A1 (fr) Composition filmogène
CA2609750A1 (fr) Composition de rasage contenant trois types de lubrifiants
KR101695834B1 (ko) 산소 투과도가 우수한 하이드로겔 마스크팩 조성물 및 이를 이용한 하이드로겔 마스크팩
JP2019510037A (ja) 抗菌ペプチド刺激性洗浄組成物
JP2011136951A (ja) 水性化粧料
US20190365617A1 (en) Rinse-off cleansing compositions comprising materials that modify sebum
EP2559420B1 (fr) Article d'épilation efficace
WO2019028248A1 (fr) Systèmes et méthodes pour améliorer l'administration d'agents actifs topiques
WO2011103233A1 (fr) Article dépilatoire efficace
JP6430794B2 (ja) 皮膚用化粧料
EP2356968A1 (fr) Enthaarungsartikel auf Substratbasis
US20110197371A1 (en) Efficient Depilatory Article
JP6778571B2 (ja) シート化粧料
JP4085667B2 (ja) 透明ゲル状洗浄剤組成物
JP2021011447A (ja) パック剤
JP2015519376A (ja) ポリマー粒子の水性分散液、それを含有する膜形成組成物、及びその使用
KR20150067823A (ko) 워시 오프 타입 팩 화장료 조성물
CA2894834A1 (fr) Copolymeres de pvoh pour applications de soins personnels
CN104583293A (zh) 防腐剂混合物及用其稳定的聚合物溶液

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18841857

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18841857

Country of ref document: EP

Kind code of ref document: A1